Abstract 1126P
Background
For patients with EGFR WT NSQ aNSCLC who are not eligible for tyrosine kinase inhibitors (TKIs), platinum-based chemotherapy with or without immunotherapy is 1L standard of care followed by 2L docetaxel at disease progression. Newer biomarker driven therapies are being developed in this patient population; thus, the goal of this study was to assess outcomes with the current standard of care using real world data.
Methods
This retrospective cohort study assesses real world overall survival (OS), progression-free survival (PFS), time to next treatment or death (TTNTD), and time to treatment discontinuation (TTD) for patients with EGFR WT NSQ aNSCLC receiving 2L docetaxel post 1L platinum-based chemotherapy plus pembrolizumab. This study used the nationwide Flatiron Health electronic health record (HER)-derived de-identified database to select adult community-based patients who had a confirmed diagnosis between Jan-01, 2017 and Dec-31, 2021 and with an ECOG PS of 0-1 at 2L initiation. Time to event outcomes were analyzed by Kaplan–Meier method.
Results
A total of 225 patients (58.2% male, mean [SD=8.6], age of 66 years) were included in the analysis; 138 (61.3%) patients were 65 years or older, 199 (88.4%) had an initial diagnosis at stage III or above, and 41 (18.2%) had brain metastasis. Among the 225 patients eligible for the analysis, the number of events observed for OS, PFS, TTNTD, and TTD were 151, 167, 180, and 185, respectively. The overall median OS (mOS) was 7.4 months (95% CI: 6.6-9.3), and mPFS was 4.3 months (95% CI: 3.8-5.3). The mTTNTD was 5.5 months and mTTD was 3.5 months.
Conclusions
This study provides valuable information on real world treatment characteristics associated with standard of care and demonstrates that high unmet need still exists for novel treatment options that further improve OS in patients with EGFR WT NSQ aNSCLC.
Clinical trial identification
Editorial acknowledgement
Medical writing support was provided by Gina E. Elsen, PhD, of AbbVie and funded by AbbVie.
Legal entity responsible for the study
AbbVie.
Funding
AbbVie.
Disclosure
D.R. Camidge: Financial Interests, Institutional, Advisory Role: AbbVie, Apollomics, AstraZeneca, Daiichi Sankyo, Elevation, Kestrel, Nuvalent, Seattle Genetics, Takeda, Turning Point, Amgen, Anchiano, Bio-Thera, BMS, Eisai, EMD Serono, Eli Lilly, GSK, Helsinn, Janssen, OnKure, Mersana, Pfizer, Qilu, Roche, Sanofi, CBT; Financial Interests, Institutional, Research Grant: Inivata; Financial Interests, Institutional, Other, Company-sponsored trials at institution: AbbVie, AstraZeneca, Dizal, Inhibrx, Karyopharm, Pfizer, Phosplatin, PsiOxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point. S. Karve, Q. Xu, S. Ng, R. Kamalakar, C.K. Ratajczak: Financial Interests, Institutional, Full or part-time Employment: AbbVie. S. Lu: Financial Interests, Institutional, Research Grant: AstraZeneca, Hutchison MediPharma, BMS, Hengrui Therapeutics, BeiGene, Roche, Hansoh; Financial Interests, Institutional, Other, Speaker fees: AstraZeneca, Roche, Hansoh, Hengrui Therapeutics; Financial Interests, Institutional, Advisory Role: AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, Simcere, Zai Lab, GenomiCare, Yuhan Corporation, prIME Oncology, Menarini, Roche.